Home › Atopic Dermatitis (Eczema) › Alabama
Atopic Dermatitis (Eczema) clinical trials in Alabama
9 studies for Atopic Dermatitis (Eczema) are looking for participants at sites in Alabama.
Cities in Alabama
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
RecruitingObservational study
Ages 12 and older · All sexes · Updated Sep 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
RecruitingPhase 3
Ages 2 to 11 · All sexes · Updated Sep 25, 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Aug 28, 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
RecruitingPhase 3
6 Months – 11 Years · All sexes · Updated Jul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
RecruitingPhase 3
Ages 18 to 63 · All sexes · Updated Jul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 4, 2026 · NCT05995964From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.